Accéder au contenu
Merck

Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera.

Antibodies (Basel, Switzerland) (2022-01-26)
Myriam Belén González Viacava, Augusto Varese, Ignacio Mazzitelli, Laura Lanari, Lucía Ávila, María Julia García Vampa, Jorge Geffner, Osvaldo Cascone, José Christian Dokmetjian, Adolfo Rafael de Roodt, Matías Fingermann
RÉSUMÉ

Mass-vaccination against COVID-19 is still a distant goal for most low-to-middle income countries. The experience gained through decades producing polyclonal immunotherapeutics (such as antivenoms) in many of those countries is being redirected to develop similar products able to neutralize SARS-CoV-2 infection. In this study we analyzed the biological activity (viral neutralization or NtAb) and immunochemical properties of hyperimmune horses' sera (HHS) obtained during initial immunization (I) and posterior re-immunization (R) cycles using the RBD domain of the SARS-CoV-2 spike protein as antigen. HHS at the end of the R cycle showed higher NtAb titers when compared to those after the I cycle (35,585 vs. 7000 mean NtAb, respectively). Moreover, this increase paralleled an increase in avidity (95.2% to 65.2% mean avidity units, respectively). The results presented herein are relevant for manufacturers of these therapeutic tools against COVID-19.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Horse IgG (whole molecule)−Peroxidase antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution